288. Autoimmune acquired coagulation factor deficiency Disease details / Clinical trials / Drug dev / DR info

ADVATE (rAHF - PFM)   
   Baxter Innovations GmbH
      2012   Phase 3   EUCTR2010-024108-84-ES   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-NL   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-DE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-BG   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024108-84-GB   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024108-84-BE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-024108-84-SE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-024108-84-AT   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
ADVATE (rAHF-PFM)   
   BAXTER INNOVATIONS GMBH
      2011   -   EUCTR2010-024108-84-IT   Australia;Austria;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
   Baxter Innovations GmbH
      2012   Phase 3   EUCTR2010-024108-84-ES   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-NL   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-DE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-BG   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024108-84-GB   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024108-84-BE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-024108-84-SE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-024108-84-AT   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
ADVATE 1000 IU powder and solvent for solution for injection   
   BAXALTA INNOVATIONS GMBH
      2019   Phase 3   EUCTR2018-003453-16-IT   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
   Baxalta Innovations GmbH
      2020   Phase 3   EUCTR2018-003453-16-AT   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2018-003453-16-NL   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003453-16-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003453-16-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003453-16-DE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
ADVATE 1000IU powder and solvent for solution for injection   
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
ADVATE 500 IU powder and solvent for solution for injection   
   BAXALTA INNOVATIONS GMBH
      2019   Phase 3   EUCTR2018-003453-16-IT   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
   Baxalta Innovations GmbH
      2020   Phase 3   EUCTR2018-003453-16-AT   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2018-003453-16-NL   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003453-16-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003453-16-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003453-16-DE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
ALPHANATE*INF 1F 1000UI+F 10ML   
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom;
ALPHANATE*INF 1F 1500UI+F 10ML   
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom;
ALPHANATE*INF 1F 250UI+F 5ML   
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom;
ALPHANATE*INF 1F 500UI+F 5ML   
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom;
APCC, aPCC + TXA   
   Oslo University Hospital
      2011   Phase 4   NCT01800435   Norway;
ARC 1779   
   Archemix Corp.
      2007   -   EUCTR2007-004371-19-AT   Austria;
ARC1779   
   Archemix Corp.
      2008   Phase 2   NCT00694785   -
      2008   Phase 2   NCT00632242   Austria;
   Medical University of Vienna, Dept. of Clinical Pharmacology
      2009   -   EUCTR2008-008532-82-AT   Austria;
ARC1779 Injection   
   Archemix Corp.
      2007   -   EUCTR2007-004371-19-AT   Austria;
Alphanate 1000 I.U.   
   Prof Flora Peyvandi, MD
      2012   Phase 3   EUCTR2006-001383-23-GB   Germany;Italy;Spain;United Kingdom;
Alphanate 1500 I.U.   
   Prof Flora Peyvandi, MD
      2012   Phase 3   EUCTR2006-001383-23-GB   Germany;Italy;Spain;United Kingdom;
Alphanate SD/HT   
   Grifols Biologicals, LLC
      2007   Phase 4   NCT00555555   United States;
Antihemophilic Factor (Recombinant)   
   Baxalta now part of Shire
      2017   Phase 3   NCT02932618   Austria;Belgium;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
   Takeda
      2017   Phase 3   NCT02973087   Canada;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United States;
BAX 111   
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
BAX111   
   BAXTER INNOVATIONS GMBH
      2011   -   EUCTR2010-024108-84-IT   Australia;Austria;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-024108-84-ES   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-NL   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-DE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-BG   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024108-84-GB   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024108-84-BE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-024108-84-SE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-024108-84-AT   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
BIVV001 (rFVIIIFc-VWF-XTEN)   
   BIOVERATIV THERAPEUTICS INC
      2020   Phase 3   EUCTR2019-002023-15-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
   Bioverativ Therapeutics Inc.
      2020   Phase 3   EUCTR2019-002023-15-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002023-15-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002023-15-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002023-15-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
   Bioverativ Therapeutics Inc. (a Sanofi company)
      2020   Phase 3   EUCTR2019-002023-15-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002023-15-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-002023-15-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      -   Phase 3   EUCTR2019-002023-15-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      -   Phase 3   EUCTR2019-002023-15-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
Biostate   
   CSL Behring
      2010   Phase 3   NCT01224808   Bulgaria;Germany;Poland;Russian Federation;Ukraine;
      2010   Phase 3   NCT01213446   Belarus;Georgia;Germany;Guatemala;Lebanon;Mexico;Ukraine;
   CSL Behring GmbH
      2011   -   EUCTR2009-017301-11-DE   Bulgaria;Germany;Poland;Russian Federation;Ukraine;
      2010   -   EUCTR2009-017753-34-DE   Belarus;European Union;Georgia;Germany;Guatemala;Lebanon;Mexico;Ukraine;
      2010   -   EUCTR2009-017301-11-PL   Bulgaria;Germany;Poland;Russian Federation;Ukraine;
      2010   -   EUCTR2009-017301-11-BG   Bulgaria;Germany;Poland;Russian Federation;Ukraine;
      -   Phase 3   EUCTR2009-017753-34-BG   Belarus;Bulgaria;European Union;Georgia;Germany;Guatemala;Lebanon;Mexico;Ukraine;
Biostate®   
   CSL Behring
      2009   Phase 2/Phase 3   NCT00941616   Brazil;Bulgaria;Poland;Russian Federation;Ukraine;
   CSL Behring GmbH
      2009   -   EUCTR2008-004922-18-BG   Bulgaria;
Blood coagulation Factor VIII and vWF, human   
   CSL Behring
      2001   Phase 4   NCT00168090   United States;
Blood sample   
   University Hospital, Lille
      2021   -   NCT04119908   -
Bortezomib   
   Institute of Hematology& Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
      2020   Phase 4   ChiCTR2000035067   China;
   Peking Union Medical College Hospital
      2018   Phase 2   NCT03700229   China;
Catridecacog   
   Novo Nordisk A/S
      2010   Phase 3   EUCTR2009-016869-28-GB   United Kingdom;
      2010   -   EUCTR2010-020192-23-GB   Austria;Denmark;Finland;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2008-007883-41-AT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2009   Phase 3   NCT00978380   Austria;Canada;Finland;France;Germany;Israel;Italy;Japan;Spain;Switzerland;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-007883-41-GB   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-007883-41-FR   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-007883-41-FI   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-007883-41-ES   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-007883-41-DE   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   NCT00713648   Austria;Canada;Finland;France;Germany;Israel;Italy;Spain;Switzerland;United Kingdom;United States;
      2008   Phase 3   EUCTR2006-003148-51-GB   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2006-003148-51-FR   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2006-003148-51-FI   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2006-003148-51-DE   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2006-003148-51-AT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2003   Phase 1   NCT00056589   United States;
Cluvot   
   CSL Behring LLC
      -   -   EUCTR2014-003764-20-Outside-EU/EEA   United States;
Coagadex   
   Bio Products Laboratory
      2018   -   NCT03161626   United States;
Coagulación factor VIII   
   Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico
      2012   Phase 3   EUCTR2006-001383-23-ES   Germany;Italy;Spain;United Kingdom;
Coagulation factor VIII   
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom;
Coagulation factor XIII   
   NOVO NORDISK
      2009   -   EUCTR2008-007883-41-IT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2006-003148-51-IT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
Cyclophosphamide   
   Zhang Lei
      2017   Phase 3   NCT03384277   China;
DDAVP (Desmopressin)   
   Rigshospitalet, Copenhagen
      2006   Phase 4   EUCTR2005-004496-38-DK   Denmark;
Desmopressin   
   Pontificia Universidad Catolica de Chile
      2009   Phase 4   NCT01994330   Chile;
Desmopressin Acetate   
   Centers for Disease Control and Prevention
      2001   -   NCT00111215   United States;
Desmopressin acetate   
   Archemix Corp.
      2007   -   EUCTR2007-004371-19-AT   Austria;
Desmopressine   
   Academic Medical Center
      2009   -   EUCTR2009-017060-17-NL   Netherlands;
Efanesoctocog alfa   
   Bioverativ Therapeutics Inc. (a Sanofi company)
      2020   Phase 3   EUCTR2019-002023-15-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002023-15-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-002023-15-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      -   Phase 3   EUCTR2019-002023-15-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      -   Phase 3   EUCTR2019-002023-15-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
Efanesoctocog alfa (BIVV001)   
   Bioverativ, a Sanofi company
      2021   Phase 1   NCT04770935   France;United States;
      2019   Phase 3   NCT04161495   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
Emicizumab   
   Hoffmann-La Roche
      2020   Phase 3   NCT04158648   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;South Africa;Spain;United Kingdom;United States;
   Indiana Hemophilia &Thrombosis Center, Inc.
      2021   Phase 4   NCT04567511   United States;
Emicizumab (ACE910, RO5534262)   
   Chugai Pharmaceutical Co., Ltd.
      2020   Phase 3   JPRN-JapicCTI-205151   Japan;
Emicizumab Injection   
   GWT-TUD GmbH
      2021   Phase 2   NCT04188639   Austria;Germany;
Eqwilate   
   Octapharma
      2019   -   NCT04106908   France;
F13CD   
   NOVO NORDISK
      2008   -   EUCTR2006-003148-51-IT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
F8VR   
   LFB BIOTECHNOLOGIES
      2011   -   EUCTR2010-023666-46-PL   Poland;
FACTANE 200 IU/ml   
   LFB BIOTECHNOLOGIES
      2011   -   EUCTR2010-023666-46-PL   Poland;
FANHDI 100 UI   
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom;
FANHDI 25 UI   
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom;
FANHDI 250UI*1F 250UI+F 10ML   
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom;
FANHDI 50 UI   
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom;
FANHDI*INF FL 250UI+SIR SOLV+S   
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom;
FANHDI*INF FL 500UI+SIR SOLV+S   
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom;
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom;
FANHDI*INF FL1000UI+SIR SOLV+S   
   FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
      2006   Phase 3   EUCTR2006-001383-23-IT   Germany;Italy;Spain;United Kingdom;
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom;
FANHDI*INF FL250UI+SIR SOLV+S   
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom;
FXIII Concentrate (Human)   
   CSL Behring
      2009   Phase 3   NCT00885742   Spain;United States;
      2009   Phase 2   NCT00883090   Spain;United States;
FXIII Concentrate (Human) (FXIII)   
   CSL Behring
      2009   Phase 3   NCT00945906   United States;
Factor VIII concentrate   
   ZLB Behring LLC
      2005   -   EUCTR2004-004868-69-SE   Sweden;
      2005   -   EUCTR2004-004868-69-AT   Austria;Sweden;
Factor XIII   
   Masaryk Hospital Krajská zdravotní a.s.
      2018   -   NCT03634215   -
Factor XIII Concentrate (Human)   
   CSL Behring LLC
      -   -   EUCTR2014-003764-20-Outside-EU/EEA   United States;
Factor XIII Concentrate (Human), Pasteurized   
   CSL Behring LLC
      2009   -   EUCTR2009-010722-19-ES   Spain;
      2009   -   EUCTR2009-010387-41-ES   Spain;
Factor von Willebrand   
   OCTAPHARMA AG
      2006   Phase 2   EUCTR2005-001426-84-FR   Czech Republic;France;Germany;
Fanhdi   
   Instituto Grifols S.A.
      2013   -   EUCTR2012-003450-92-ES   Spain;
Fanhdi 100 UI FVIII-120 UI FVW   
   Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico
      2012   Phase 3   EUCTR2006-001383-23-ES   Germany;Italy;Spain;United Kingdom;
Fanhdi 25 UI FVIII-30 UI FVW   
   Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico
      2012   Phase 3   EUCTR2006-001383-23-ES   Germany;Italy;Spain;United Kingdom;
Fanhdi 50 UI FVIII-60 UI FVW   
   Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico
      2012   Phase 3   EUCTR2006-001383-23-ES   Germany;Italy;Spain;United Kingdom;
Fibrinogen   
   Masaryk Hospital Krajská zdravotní a.s.
      2018   -   NCT03634215   -
Fibrogammin P   
   Children's Hospital of Orange County
      2000   -   NCT00640289   United States;
Fibrogammin® P   
   CSL Behring LLC
      2009   -   EUCTR2009-010722-19-ES   Spain;
Fibrogammin®P   
   CSL Behring LLC
      2009   -   EUCTR2009-010387-41-ES   Spain;
HEMOFIX   
   Hadassah Medical Organization
      2016   -   NCT01651468   Israel;
HUMAN COAGULATION FACTOR VIII, VON WILLEBRAND FACTOR COMPLEX   
   Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      2013   Phase 3   EUCTR2006-001383-23-DE   Germany;Italy;Spain;United Kingdom;
Haemate P   
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands;
Haemate P® (Human Coagulation Factor VIII)   
   Bio Products Laboratory
      2004   Phase 2   NCT02250508   Israel;
Haemate-P, Wilate   
   Centre of Thrombosis and Haemostasis
      2007   -   EUCTR2007-004943-31-SE   Sweden;
Haemate® P 250   
   Octapharma AG
      2008   Phase 2   EUCTR2008-001910-25-SK   Slovakia;
Hemlibra®   
   GWT-TUD GmbH
      2021   Phase 2   EUCTR2019-004430-42-DE   Austria;Germany;
      2021   Phase 2   EUCTR2019-004430-42-AT   Austria;Germany;
Human VWF/FVIII concentrate   
   Octapharma
      2011   Phase 3   NCT01365546   Bulgaria;India;Italy;Oman;Poland;Romania;South Africa;Turkey;United States;
Human coagulation Factor VIII / von Willebrand Factor   
   CSL Limited
      -   -   EUCTR2014-005401-20-Outside-EU/EEA   Australia;
Human coagulation factor VIII   
   OCTAPHARMA AG
      2006   Phase 2   EUCTR2005-001426-84-FR   Czech Republic;France;Germany;
Human coagulation factor VIII associated with Von Willebrand factor (VWF)   
   Bio Products Laboratory
      -   Phase 3   EUCTR2006-000664-85-PL   Poland;United Kingdom;
Human coagulation factor VIII associated with von Willebrand factor (VWF)   
   Bio Products Laboratory
      -   Phase 3   EUCTR2006-000663-28-PL   Poland;United Kingdom;
Human factor X   
   Bio Products Laboratory
      2009   -   EUCTR2009-011145-18-ES   Germany;Spain;United Kingdom;
   Bio Products Laboratory Limited
      2015   Phase 3   EUCTR2012-003093-98-GB   Turkey;United Kingdom;
      2012   -   EUCTR2009-015086-31-ES   Germany;India;Spain;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015086-31-GB   Germany;India;Spain;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-011145-18-DE   Germany;Spain;United Kingdom;
   Bio Products Laboratory Ltd
      2009   -   EUCTR2009-011145-18-GB   Germany;Spain;Turkey;United Kingdom;United States;
Human von Willebrand factor (VWF) and coagulation factor VIII (FVIII)   
   Octapharma AG
      2011   -   EUCTR2010-021162-30-BG   Bulgaria;India;Italy;Russian Federation;Turkey;United States;
Human von Willebrand factor (vWF) and coagulation factor VIII (FVIII)   
   OCTAPHARMA AG
      2011   -   EUCTR2010-021162-30-IT   Bulgaria;India;Italy;Russian Federation;Turkey;United States;
Humate-P   
   ZLB Behring LLC
      2005   -   EUCTR2004-004868-69-SE   Sweden;
      2005   -   EUCTR2004-004868-69-AT   Austria;Sweden;
Marketed plasma-derived VWF/FVIII concentrate   
   Baxalta now part of Shire
      2008   Phase 1   NCT00816660   Austria;Canada;Germany;Italy;United Kingdom;United States;
Minirin   
   Archemix Corp.
      2007   -   EUCTR2007-004371-19-AT   Austria;
Minrin   
   Academic Medical Center
      2009   -   EUCTR2009-017060-17-NL   Netherlands;
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands;
NN 1841   
   Novo Nordisk A/S
      2010   Phase 3   EUCTR2009-016869-28-GB   United Kingdom;
NN1841   
   Novo Nordisk A/S
      2010   -   EUCTR2010-020192-23-GB   Austria;Denmark;Finland;France;Germany;Italy;Spain;Sweden;United Kingdom;
Natriumchlorid 0,   
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria;
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria;
Neumega (Oprelvekin, Interleukin 11, IL-11)   
   Margaret Ragni
      2008   Phase 2   NCT00524225   United States;
   University of Pittsburgh
      2010   Phase 2   NCT00994929   United States;
OBI-1   
   Baxalta now part of Shire
      2014   -   NCT01968655   United States;
      2010   Phase 2/Phase 3   NCT01178294   Canada;France;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States;
   Baxter Innovations GmbH
      2012   -   EUCTR2011-000181-34-SE   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-000181-34-HU   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-000181-34-DE   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States;
      2011   -   EUCTR2011-000181-34-GB   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States;
   INSPIRATION BIOPHARMACEUTICALS
      2012   -   EUCTR2011-000181-34-IT   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States;
OCTANATE 100 UI/ml, poudre et solvant pour solution injectable   
   OCTAPHARMA AG
      2007   -   EUCTR2005-004435-22-FR   Czech Republic;France;
OCTANATE 50 UI/ml, poudre et solvant pour solution injectable   
   OCTAPHARMA AG
      2007   -   EUCTR2005-004435-22-FR   Czech Republic;France;
Obyoctocog alfa   
   Baxter Innovations GmbH
      2012   -   EUCTR2011-000181-34-SE   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-000181-34-HU   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-000181-34-DE   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States;
      2011   -   EUCTR2011-000181-34-GB   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States;
Octocog alfa   
   Spanish Society of Thrombosis and Haemostasis
      2016   -   NCT03006965   Spain;
Octostim   
   Archemix Corp.
      2007   -   EUCTR2007-004371-19-AT   Austria;
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands;
   Rigshospitalet, Copenhagen
      2006   Phase 4   EUCTR2005-004496-38-DK   Denmark;
Oprelvekin, Interleukin 11, IL-11   
   Margaret Ragni
      2008   Phase 2   NCT00524342   United States;
Optivate   
   Bio Products Laboratory
      2007   Phase 3   NCT00404300   Israel;United Kingdom;
      2006   Phase 3   NCT00387192   Israel;United Kingdom;
      2006   Phase 3   EUCTR2006-000664-85-GB   Poland;United Kingdom;
      2006   Phase 3   EUCTR2006-000663-28-GB   Poland;United Kingdom;
      -   Phase 3   EUCTR2006-000663-28-PL   Poland;United Kingdom;
Optivate® (Human Coagulation Factor VIII)   
   Bio Products Laboratory
      2004   Phase 2   NCT02250508   Israel;
      2001   Phase 3   NCT02246881   Poland;United Kingdom;
Physiologische Kochsalzlösung Fresenius - Infusionslösung   
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria;
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria;
Phytomenadione   
   Region Skane
      2019   -   NCT03782025   Sweden;
Plasma-derived FVIII/VWF concentrate   
   Grifols Therapeutics LLC
      2013   Phase 4   NCT02472665   Spain;
Prednisone   
   Georgetown University
      2006   Phase 2/Phase 3   NCT00306670   United States;
RECOMBINANT HUMAN COAGULATION FACTOR VIII FC - VON WILLEBRAND FACTO   
   BIOVERATIV THERAPEUTICS INC
      2020   Phase 3   EUCTR2019-002023-15-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
RECOMBINANT HUMAN COAGULATION FACTOR VIII FC - VON WILLEBRAND FACTOR - XTEN FUSION PROTEIN   
   Bioverativ Therapeutics Inc.
      2020   Phase 3   EUCTR2019-002023-15-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002023-15-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002023-15-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002023-15-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
   Bioverativ Therapeutics Inc. (a Sanofi company)
      2020   Phase 3   EUCTR2019-002023-15-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002023-15-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-002023-15-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      -   Phase 3   EUCTR2019-002023-15-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      -   Phase 3   EUCTR2019-002023-15-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
RECOMBINANT HUMAN COAGULATION FACTOR VIII FC - VON WILLEBRAND FACTOR -XTEN FUSION PROTEIN   
   BIOVERATIV THERAPEUTICS INC
      2020   Phase 3   EUCTR2019-002023-15-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
RFVIII   
   Baxalta now part of Shire
      2019   Phase 3   NCT03879135   France;Italy;Netherlands;Russian Federation;Spain;Turkey;United States;
RFVIIa, rFVIIa + TXA   
   Oslo University Hospital
      2011   Phase 4   NCT01800435   Norway;
RO5534262 EMICIZUMAB   
   GWT-TUD GmbH
      2021   Phase 2   EUCTR2019-004430-42-DE   Austria;Germany;
      2021   Phase 2   EUCTR2019-004430-42-AT   Austria;Germany;
RVWF   
   BAXTER INNOVATIONS GMBH
      2011   -   EUCTR2010-024108-84-IT   Australia;Austria;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
   Baxalta now part of Shire
      2019   Phase 3   NCT03879135   France;Italy;Netherlands;Russian Federation;Spain;Turkey;United States;
   Baxter Innovations GmbH
      2012   Phase 3   EUCTR2010-024108-84-ES   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-NL   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-DE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-BG   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024108-84-GB   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024108-84-BE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-024108-84-SE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-024108-84-AT   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Recombinant Factor XIII   
   NOVO NORDISK
      2009   -   EUCTR2008-007883-41-IT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2006-003148-51-IT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
Recombinant Factor XIII (rFXIII)   
   Novo Nordisk A/S
      2008   Phase 3   EUCTR2006-003148-51-GB   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2006-003148-51-FR   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2006-003148-51-FI   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2006-003148-51-DE   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2006-003148-51-AT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
Recombinant Von Willebrand factor   
   Margaret Ragni
      2021   Phase 3   NCT04344860   United States;
Recombinant coagulation FVIII Fc – von Willebrand factor – XTEN fusion protein   
   BIOVERATIV THERAPEUTICS INC
      2020   Phase 3   EUCTR2019-002023-15-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
   Bioverativ Therapeutics Inc.
      2020   Phase 3   EUCTR2019-002023-15-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002023-15-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002023-15-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002023-15-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
   Bioverativ Therapeutics Inc. (a Sanofi company)
      2020   Phase 3   EUCTR2019-002023-15-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002023-15-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-002023-15-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      -   Phase 3   EUCTR2019-002023-15-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
      -   Phase 3   EUCTR2019-002023-15-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
Recombinant coagulation FVIII Fc –von Willebrand factor – XTEN fusion protein   
   BIOVERATIV THERAPEUTICS INC
      2020   Phase 3   EUCTR2019-002023-15-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United Kingdom;United States;
Recombinant factor VIIII (rFVIII)   
   Baxalta now part of Shire
      2011   Phase 3   NCT01410227   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Recombinant factor XIII (rFXIII)   
   Novo Nordisk A/S
      2010   Phase 3   EUCTR2009-016869-28-GB   United Kingdom;
      2010   -   EUCTR2010-020192-23-GB   Austria;Denmark;Finland;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2008-007883-41-AT   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-007883-41-GB   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-007883-41-FR   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-007883-41-FI   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-007883-41-ES   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-007883-41-DE   Austria;Finland;France;Germany;Italy;Spain;United Kingdom;
Recombinant human von Willebrand Factor   
   Baxalta Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Recombinant interleukin-11   
   University of Pittsburgh
      2004   Phase 2   NCT00151125   United States;
Recombinant porcine coagulation factor VIII (B domain deleted)   
   INSPIRATION BIOPHARMACEUTICALS
      2012   -   EUCTR2011-000181-34-IT   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States;
Recombinant porcine coagulation factor VIII (B-domain deleted)   
   Baxter Innovations GmbH
      2011   -   EUCTR2011-000181-34-GB   Canada;Germany;Hungary;India;Italy;Sweden;United Kingdom;United States;
Recombinant von Willebrand Factor   
   Baxalta Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Recombinant von Willebrand Factor (rVWF)   
   Baxalta now part of Shire
      2015   Phase 3   NCT02283268   Australia;Austria;Czech Republic;Czechia;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Recombinant von Willebrand Factor 1300IU   
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Recombinant von Willebrand Factor 650IU   
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Recombinant von Willebrand factor   
   Margaret Ragni
      2019   Phase 3   NCT02606045   United States;
Recombinant von Willebrand factor (rVWF)   
   Baxalta now part of Shire
      2011   Phase 3   NCT01410227   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)   
   Baxalta now part of Shire
      2008   Phase 1   NCT00816660   Austria;Canada;Germany;Italy;United Kingdom;United States;
Recomibnant human Von Willebrand Factor   
   Baxalta Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-NL   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-GB   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-DE   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-CZ   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-AT   Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Baxter Innovations GmbH
      2015   Phase 3   EUCTR2014-003575-38-IT   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003575-38-ES   Argentina;Australia;Austria;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Rituxan   
   Georgetown University
      2006   Phase 2/Phase 3   NCT00306670   United States;
Rituximab   
   Peking Union Medical College Hospital
      2018   Phase 2   NCT03700229   China;
   Zhang Lei
      2017   Phase 3   NCT03384277   China;
Rurioctocog alfa pegol   
   Spanish Society of Thrombosis and Haemostasis
      2016   -   NCT03006965   Spain;
SODIUM CHLORIDE SOLUTION   
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria;
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria;
Saline Solution   
   Tirol Kiniken GmbH
      2018   Phase 2   NCT03613584   Austria;
Simvastatine   
   Academic Medical Center
      2009   -   EUCTR2009-017060-17-NL   Netherlands;
Steroid   
   Zhang Lei
      2017   Phase 3   NCT03384277   China;
Sublingual videomicroscopy   
   University Hospital, Lille
      2021   -   NCT04119908   -
TAK-672   
   Takeda
      2021   Phase 2/Phase 3   NCT04580407   Japan;
Tranexamic Acid Injection [Cyklokapron]   
   Margaret Ragni
      2021   Phase 3   NCT04344860   United States;
Tranexamic acid   
   Bloodworks
      2019   -   NCT04146376   United States;
   Margaret Ragni
      2019   Phase 3   NCT02606045   United States;
Uterine   
   Cairo University
      2015   -   NCT03871764   -
VEYONDI 650IU powder and solvent for solution for injection   
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
VEYVONDI 1300I IU powder and solvent for solution for injection   
   Baxalta Innovations GmbH
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
VEYVONDI 1300IU powder and solvent for solution for injection   
   BAXALTA INNOVATIONS GMBH
      2019   Phase 3   EUCTR2018-003453-16-IT   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
   Baxalta Innovations GmbH
      2020   Phase 3   EUCTR2018-003453-16-AT   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2018-003453-16-NL   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003453-16-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003453-16-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003453-16-DE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States;
VEYVONDI 650IU powder and solvent for solution for injection   
   BAXALTA INNOVATIONS GMBH
      2019   Phase 3   EUCTR2018-003453-16-IT   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
   Baxalta Innovations GmbH
      2020   Phase 3   EUCTR2018-003453-16-AT   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2018-003453-16-NL   Austria;Belgium;Canada;Czechia;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003453-16-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003453-16-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003453-16-DE   Austria;Belgium;Canada;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United States;
VWD factor VIII concentrate   
   Centre of Thrombosis and Haemostasis
      2007   -   EUCTR2007-004943-31-SE   Sweden;
VWF SD-35-DH   
   LFB BIOTECHNOLOGIES
      2005   Phase 4   EUCTR2005-001746-17-BE   Belgium;
      2005   -   EUCTR2004-005051-34-BE   Belgium;
      -   Phase 4   EUCTR2005-001746-17-PL   Belgium;Poland;
VWF replacement therapy with Wilate   
   Bloodworks
      2019   -   NCT04146376   United States;
VWF-containing products   
   Octapharma
      2019   -   NCT04053699   Belarus;Bulgaria;Croatia;Hungary;Lebanon;Moldova, Republic of;Russian Federation;Ukraine;United States;
VWF/FVIII products   
   Skane University Hospital
      2007   -   NCT00557908   Sweden;United States;
Vessel   
   Cairo University
      2015   -   NCT03871764   -
Veyvondi   
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands;
Von Willebrand Factor Antigen   
   ZLB Behring LLC
      2005   -   EUCTR2004-004868-69-SE   Sweden;
      2005   -   EUCTR2004-004868-69-AT   Austria;Sweden;
Von Willebrand Factor Ristocetin Cofactor   
   ZLB Behring LLC
      2005   -   EUCTR2004-004868-69-SE   Sweden;
      2005   -   EUCTR2004-004868-69-AT   Austria;Sweden;
Von Willebrand Faktor   
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria;
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria;
Von Willebrand factor (Recombinant)   
   Baxalta now part of Shire
      2017   Phase 3   NCT02932618   Austria;Belgium;Czechia;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
   Takeda
      2017   Phase 3   NCT02973087   Canada;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United States;
Von Willebrand factor and coagulation factor VIII in combination   
   Octapharma AG
      2008   Phase 2   EUCTR2008-001910-25-SK   Slovakia;
Voncento   
   CSL Behring
      2015   Phase 4   NCT02552576   Austria;Germany;Greece;Ireland;Poland;United Kingdom;
   CSL Behring GmbH
      2016   Phase 4   EUCTR2013-003305-25-GR   Austria;Germany;Greece;Ireland;Poland;United Kingdom;
      2015   Phase 4   EUCTR2013-003305-25-IE   Austria;Germany;Greece;Ireland;Poland;United Kingdom;
      2015   Phase 4   EUCTR2013-003305-25-GB   Austria;Germany;Greece;Ireland;Poland;United Kingdom;
      2015   Phase 4   EUCTR2013-003305-25-DE   Austria;Germany;Greece;Ireland;Poland;United Kingdom;
      2015   Phase 4   EUCTR2013-003305-25-AT   Austria;Germany;Greece;Ireland;Poland;United Kingdom;
      2015   -   EUCTR2013-003305-25-PT   Ireland;Portugal;United Kingdom;
      -   Phase 4   EUCTR2013-003305-25-PL   Austria;Germany;Greece;Ireland;Poland;United Kingdom;
Voncento, Biostate®   
   CSL Limited
      -   -   EUCTR2014-005401-20-Outside-EU/EEA   Australia;
Voncento®   
   CSL Behring
      2015   -   NCT04657887   France;
Vonicog alfa   
   BAXTER INNOVATIONS GMBH
      2011   -   EUCTR2010-024108-84-IT   Australia;Austria;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2016-001478-14-FR   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-NL   Austria;Belgium;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-FR   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001477-33-DE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-NL   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-IT   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-FI   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-ES   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-DE   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001478-14-CZ   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-IT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-GB   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-ES   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-CZ   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001477-33-BE   Austria;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-001477-33-AT   Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2016-001478-14-GB   Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   Baxter Innovations GmbH
      2012   Phase 3   EUCTR2010-024108-84-ES   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-NL   Australia;Austria;Belgium;Bulgaria;Canada;France;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-DE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-024108-84-BG   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024108-84-GB   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024108-84-BE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-024108-84-SE   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-024108-84-AT   Australia;Austria;Belgium;Bulgaria;Canada;Germany;India;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
WILATE 1000 I.U.   
   Octapharma AG
      2011   -   EUCTR2010-021162-30-BG   Bulgaria;India;Italy;Russian Federation;Turkey;United States;
WILATE 450   
   OCTAPHARMA AG
      2006   Phase 2   EUCTR2005-001426-84-FR   Czech Republic;France;Germany;
WILATE 500 I.U.   
   Octapharma AG
      2011   -   EUCTR2010-021162-30-BG   Bulgaria;India;Italy;Russian Federation;Turkey;United States;
WILATE 900   
   OCTAPHARMA AG
      2006   Phase 2   EUCTR2005-001426-84-FR   Czech Republic;France;Germany;
WILATE® 450   
   Octapharma AG
      2008   Phase 2   EUCTR2008-001910-25-SK   Slovakia;
WILFACTIN   
   LFB BIOTECHNOLOGIES
      2010   Phase 3   EUCTR2007-004116-32-BE   Belgium;France;
      2008   -   EUCTR2007-004116-32-FR   Belgium;France;
      2005   Phase 4   EUCTR2005-001746-17-BE   Belgium;
      2005   -   EUCTR2004-005051-34-BE   Belgium;
      -   Phase 4   EUCTR2005-001746-17-PL   Belgium;Poland;
Wilate   
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands;
   Octapharma
      2021   Phase 3   NCT04953884   Belarus;Moldova, Republic of;North Macedonia;Russian Federation;Ukraine;United States;
      2020   Phase 3   NCT04052698   Belarus;Bulgaria;Croatia;Hungary;Lebanon;Moldova, Republic of;Russian Federation;Ukraine;United States;
   Octapharma AG
      2008   Phase 4   EUCTR2008-000795-24-SE   Sweden;
      2007   -   EUCTR2005-001426-84-CZ   Czech Republic;France;Germany;
Wilate 1000   
   Octapharma AG
      2020   Phase 3   EUCTR2018-004675-13-HR   Belarus;Bulgaria;Croatia;Hungary;Lebanon;Russian Federation;Ukraine;United States;
      2019   Phase 3   EUCTR2018-004675-13-HU   Belarus;Bulgaria;Croatia;Czech Republic;Hungary;Lebanon;Russian Federation;Ukraine;United States;
      -   Phase 3   EUCTR2018-004675-13-BG   Belarus;Bulgaria;Croatia;Hungary;Lebanon;Russian Federation;Ukraine;United States;
Wilate 1000 I.U.   
   OCTAPHARMA AG
      2011   -   EUCTR2010-021162-30-IT   Bulgaria;India;Italy;Russian Federation;Turkey;United States;
Wilate 500   
   Octapharma AG
      2020   Phase 3   EUCTR2018-004675-13-HR   Belarus;Bulgaria;Croatia;Hungary;Lebanon;Russian Federation;Ukraine;United States;
      2019   Phase 3   EUCTR2018-004675-13-HU   Belarus;Bulgaria;Croatia;Czech Republic;Hungary;Lebanon;Russian Federation;Ukraine;United States;
      -   Phase 3   EUCTR2018-004675-13-BG   Belarus;Bulgaria;Croatia;Hungary;Lebanon;Russian Federation;Ukraine;United States;
Wilate 500 I.U.   
   OCTAPHARMA AG
      2011   -   EUCTR2010-021162-30-IT   Bulgaria;India;Italy;Russian Federation;Turkey;United States;
Wilfactin   
   Erasmus University Medical Center
      2019   Phase 4   EUCTR2018-001631-46-NL   Netherlands;
Willfact   
   Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
      2017   Phase 2   EUCTR2016-000789-53-AT   Austria;
   Tirol Kliniken GmbH
      2017   Phase 2   EUCTR2017-003036-37-AT   Austria;
Wiloctin   
   Octapharma AG
      2006   -   EUCTR2006-002857-54-DE   Germany;